Inclusion Criteria:

1. Patients with histologically proven esophageal cancer to be treated with RT with
concurrent chemotherapy to a final dose of >/=40 Gy will be included in this study.

2. Patients with mid thoracic, distal esophageal, and gastroesophageal junction tumors.

3. All patients must sign a study-specific informed consent form. If the patient's
mental status precludes his/her giving informed consent, written informed consent may
be given by the patient's legal representative.

4. Age >/= 18

5. Women of childbearing potential (A woman of child-bearing potential is a sexually
mature woman who has not undergone a hysterectomy or who has not been naturally
postmenopausal for at least 24 consecutive months [i.e., who has had menses at any
time in the preceding 24 consecutive months]. For women of childbearing potential, a
blood pregnancy test must be performed within 72 hours prior to the start of protocol
treatment.

6. Induction chemotherapy allowed.

7. Being able to meet radiation dose constraints of at-risk organs.

Exclusion Criteria:

1. Patients who receive cardiotoxic drugs, such as trastuzumab or adriamycin as part of
their chemotherapy regimen.

2. Patients with recent myocardial infarction in the past month, decompensated heart
failure or myocarditis/pericarditis in the past month.

3. Patients with renal failure indicated by a glomerular filtration rate (GFR) < 30
mL/min/1.73sq.m.

4. Patients in the intensive care unit (ICU).

5. Patients with systemic sepsis.

6. Patients with acute pulmonary embolism in the past month.

7. Women who are pregnant or nursing are not eligible as treatment involves
unforeseeable risks to the fetus or child.

8. Inability to obtain histologic proof of malignancy.

9. Patients with proximal / cervical esophageal cancer.